Zhang et al. similarly demonstrated that the inhibition of KDM6A/B using GSK-J4 induced global enhancer reprogramming, attenuated the malignant phenotype of CRC cells in vitro and in vivo, sensitized them to chemotherapy, and suppressed tumor-initiating cell characterization and stemness-associated gene signatures [29]. This evidence concerns the gene KDM6A and colorectal carcinoma.